Reactive Astrocytes (A2 Phenotype) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Reactive Astrocytes exhibiting the A2 phenotype are a protective or "benign" reactive astrocyte subtype induced by ischemia, trauma, or certain neurotrophic factors. Unlike the toxic A1 phenotype, A2 astrocytes upregulate genes involved in tissue repair, synaptic support, and neuroprotection.
A2 Reactive Astrocytes were characterized by Liddelow et al. (2017) as the neuroprotective counterpart to A1 astrocytes. They are induced by ischemia and secrete factors that promote neuronal survival and tissue repair.
¶ Markers and Identification
- Specific Markers: S100A10, PTX3 (Pentraxin 3), Bsg (Basigin), Emp1 (Epithelial Membrane Protein 1)
- Upregulated Trophic Factors: GDNF, BDNF, NGF, VEGF
- Morphology: Moderate hypertrophy, increased branching
- Species: Identified in mouse ischemia models, human stroke tissue
A2 astrocytes are induced by:
- Ischemia/Hypoxia: Primary trigger via HIF-1α pathway
- Trophic factors: CNTF, LIF, Cardiotrophin-1
- Anti-inflammatory signals: IL-10, TGF-β
- Neuronal injury signals: Without microglial activation
- Increased glutamate uptake: Via upregulated GLT-1
- Enhanced potassium buffering: Improved homeostasis
- Synaptogenic factors: Increased thrombospondins, hevin
- Trophic support: GDNF, BDNF, NGF secretion
- Wound healing: Increased proliferation
- Angiogenesis: VEGF secretion
- Blood-brain barrier support: Enhanced pericyte interaction
- Scar formation: Modulated glial scar
¶ Stroke and Ischemia
- Penumbra protection: Surrounding ischemic core
- Promote recovery: Trophic support for surviving neurons
- Angiogenesis: Support blood vessel formation
- May provide compensatory neuroprotection
- Can be induced by neurotrophic therapies
- A1/A2 balance important for progression
- Potential for neuroprotective therapy
- GDNF secretion supports dopaminergic neurons
- Target for regeneration approaches
- Essential for recovery
- Modulate glial scar
- Promote neuronal sprouting
- CNTF administration: Induce A2 phenotype
- Ischemic preconditioning: Natural A2 induction
- Anti-inflammatory drugs: Shift balance from A1
- GDNF delivery: Astrocyte-targeted gene therapy
- BDNF mimetics: Enhance trophic support
- Astrocyte transplantation: Direct cell therapy
The study of Reactive Astrocytes (A2 Phenotype) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Liddelow SA, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature.
- Zamanian JL, et al. (2012). Genomic analysis of reactive astrocytes. Journal of Neuroscience.
- Sofroniew MV. (2020). Astrocyte reactivity. Trends in Neurosciences.